Bausch Health Companies (NYSE:BHC) posted its earnings results on Tuesday. The company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.03), Morningstar.com reports. Bausch Health Companies had a negative net margin of 19.27% and a positive return on equity of 47.01%. The firm had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the prior year, the firm earned $0.93 earnings per share. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. Bausch Health Companies updated its FY 2019 guidance to EPS.
Shares of Bausch Health Companies stock traded down $0.19 during trading hours on Wednesday, reaching $22.39. 4,907,950 shares of the company’s stock were exchanged, compared to its average volume of 3,966,516. Bausch Health Companies has a 1 year low of $17.20 and a 1 year high of $28.45. The stock has a market capitalization of $7.95 billion, a P/E ratio of 5.57, a P/E/G ratio of 0.54 and a beta of 0.76. The firm has a fifty day moving average price of $24.06. The company has a debt-to-equity ratio of 8.61, a current ratio of 1.08 and a quick ratio of 0.83.
In related news, EVP Christina Ackermann sold 3,968 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $24.81, for a total value of $98,446.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.87% of the stock is owned by corporate insiders.
BHC has been the subject of several analyst reports. Wolfe Research initiated coverage on shares of Bausch Health Companies in a research note on Friday, July 19th. They issued an “outperform” rating and a $31.00 target price for the company. JPMorgan Chase & Co. upgraded shares of Bausch Health Companies from an “underweight” rating to a “neutral” rating and set a $24.80 target price for the company in a research note on Monday, May 13th. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research note on Monday, July 15th. Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Tuesday, May 21st. Finally, Mizuho set a $45.00 price objective on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Thursday, June 20th. Three analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $29.68.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.